InsiderDB
Sign inStart free trial

Biogen (BIIB)

Healthcare · Drug Manufacturers - General

12 members of Congress have disclosed 44 trades in Biogen (BIIB) since 2014: 28 buys and 16 sales. The most recent was disclosed on Oct 7, 2026. 1 trade was made by members of a committee that oversees Biogen's industry.

Trades disclosed
44
Members trading
12
Buys / sells
28 / 16
Reported value
$226K–$1M

Keep following the company.

Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.

Follow BIIB

What else is happening at BIIB

All research →

Company filings and public records connected to this stock, ordered by when they became public or were first observed.

  1. BIIBFinancial report·SEC EDGAR

    BIIB: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Oct 28, 2026, 6:23 AM EDTEvent / period: Sep 30, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  2. BIIBCompany announcement·SEC EDGAR

    BIIB: Financial results

    Filed 8-K for an event or period dated 2026-10-28. Financial results.

    Public: Oct 28, 2026, 6:07 AM EDTEvent / period: Oct 28, 2026Original source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  3. BIIBLobbying report·Lobbying disclosures

    BIIB: third_quarter 2026 lobbying report

    Issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment and Lupus. Issues related to the budget and appropriations process Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to the budget and appropriations process

    Public: Oct 20, 2026, 11:09 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  4. BIIBLobbying report·Lobbying disclosures

    BIIB: third_quarter 2026 lobbying report

    Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program. Issues related to rare disease and treatment. Drug pricing policy. Public policy around patien

    Public: Oct 20, 2026, 1:02 PM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

  5. BIIBLobbying report·Lobbying disclosures

    BIIB: third_quarter 2026 lobbying report

    Issues related to Alzheimer's disease and dementia, including screening, diagnosis, and care. Issues related to postpartum depression screening, detection, and education. Issues related to ALS, lupus, and kidney disease policy. IRA implementation. Issues related to drug pricing. 340B Program. Supply Chain. Issues related to patient affordability and access including copay and coverage reform. Issues related to PBM reform. PDUFA, drug reviews, approval pathways, PPRV Program, clinical trials. Issues related to rare diseases, including the Orphan Drug and ORPHAN CURES Act, rare disease research

    Public: Oct 19, 2026, 11:37 AM EDTOriginal source ↗

    1 congressional household disclosed purchases in the past 90 days. See the trades

Committee overlaps

Trades by members of a committee that oversees Biogen's industry. An overlap is a fact about the trade, not evidence of wrongdoing.

Who traded BIIB

All trades

From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.